Fakeeh Care Group Delivers 1H-2025 Revenue of SAR 1.51 billion, Solid 13% Year-On-Year Growth Fuelled by Group-Wide Volume and Case-Mix Gains; Attributable Profit Rises to SAR 154 million, up 28% Year-On-Year

The Group advances hub-and-spoke expansion with DSFMC Al Zahraa groundbreaking; disciplined ramp up in Riyadh and Madinah underpin medium-term growth trajectory

2Q-2025 Highlights[1]

Revenue	SAR 811.8 MN	▲ 24.1% YoY
Gross Profit	SAR 180.6 MN	▲ 11.6% YoY / 22.2% margin
Total Patients Served	465,112	▲ 16% YoY
EBITDA[1]	SAR 129.1 MN	▲ 11.2% YoY/15.9% margin
Net Profit	SAR 68.2 MN	▲ 59% YoY / 8.4% margin
Attributable Net Profit	SAR 82.1 MN	▲ 73% YoY

1H-2025 Highlights

Revenue	SAR 1,512.9 MN	▲ 13.4% YoY
Gross Profit	SAR 356.8 MN	▲ 1.8% YoY / 23.6% margin
Total Patients Served	897,309	▲ 8% YoY
EBITDA	SAR 250.2 MN	▼ 3.3% YoY / 16.5% margin
Net Profit	SAR 135.5 MN	▲ 30.9% YoY / 9% margin
Attributable Net Profit	SAR 154.3 MN	▲ 28.4% YoY

Jeddah, KSA, 06 August 2025: Dr Soliman Abdel Kader Fakeeh Hospital Company and its Subsidiaries ("Fakeeh Care Group", "FCG", "Fakeeh Care", the "Company" or the "Group"), a leading fully integrated academic healthcare provider listed on TASI (SYMBOL: 4017 and ISIN code SA562GSHUOH7), announces today its financial results[2] for the second quarter ended 30 June 2025.

Key Financial & Operational Highlights

- **Revenue Growth Momentum Sustained:** 2Q-2025 revenue reached **SAR 812 million**, up **24%** YoY (2Q-2024: **SAR 654 million**), with 1H-2025 revenue up **13%** to **SAR 1.51 billion** (1H-2024: SAR 1.33 billion) as post-Ramadan normalization, double-digit Jeddah growth and the Riyadh ramp in 2Q-2025 lifted Group turnover.

- **Broad-Based Volume Expansion & Case-Mix Tailwinds:** The Group served more than **465K patients** in 2Q-2025 **(+16% YoY)**, taking 1H volumes to over **897K (+8% YoY)**. Outpatient and inpatient volumes grew **15% and 16%,** respectively**,** in the quarter translating into combined revenue growth of **18%**. Jeddah's double-digit patient growth remained a central driver, coupled with Riyadh ramp up progression.

---

[1] *The Group calculates EBITDA as Earnings Before Interest and Tax (EBIT) plus depreciation and amortization, and non-cash Long-term Incentive Plan (LTIP).*
[2] *In accordance with the International Financial Reporting Standards (IFRS).*

- **Riyadh & Madinah Ramp; DSFMC Al Zahraa Groundbreaking: Riyadh** increased its operational beds to **102** (**71** a year earlier) and delivered in 1H 2025 **23%** growth in patients served in addition to almost **100%** rise in surgeries as higher-complexity services scale, translating to **30%** increase in hospital gross revenues. DSFH Madinah launched **48 beds** under a disciplined quality-first ramp. Construction commenced on DSFMC Al Zahraa in Jeddah—a key spoke in the hub-and-spoke strategy.

- **Operational Profitability & Margin Dynamics:** Gross profit was **SAR 181 million** in 2Q-2025, although higher by **12%** compared to same period in previous year, gross margin at **22.2%** reflects front-loaded clinical labour and ramp dilution in new hospitals partially offset by procurement discipline and integrated operational structure. Consequently, Group EBITDA in 1H 2025 reached to **SAR 250 million** (margin **16.5%**) vs **SAR 259 million** (margin **19.4%**) in 1H-2024.

- **Net Profit Expansion & Attributable Growth:** Net Profit after Tax rose **59% YoY to SAR 68 million** (2Q-2024: **SAR 43 million**) and led to **31% YoY** increase in 1H 2025 to **SAR 136 million** (1H-2024: **SAR 104 million**), driven by business performance strength, lower finance costs and higher finance income. Profit attributable to shareholders reached **SAR 154 million** in 1H-2025 (**SAR 120 million, +28% YoY**).

- **Resilient Financial Position & Conservative Leverage:** Cash & Cash equivalents including short term Sukuk investments stood at **SAR 474 million** and loans at **SAR 579 million** as at 30-Jun-2025. The Group's net debt position now reads **0.20x** Net Debt/LTM EBITDA (including leases reads **1.17x)**, preserving balance-sheet headroom for the Group's expansion program.

- **Strengthening the Integrated Healthcare Platform:** The Group maintains its expansion of the Home Healthcare network (six branches; two more targeted 4Q-2025), and roll-out of Medical Capsules extending branded primary/diagnostic access to remote geographies while reinforcing referral flows.

- **Expanding Emergency Medical Services Reach:** MedE, through the Hajj deployment (725 teams, 30 ambulances) and CSR operation of Namira Hospital during peak pilgrimage, strengthened the Group's role as a trusted national partner—showcasing scalable emergency response capabilities that complement Fakeeh Care Group's healthcare ecosystem.

- **JCI Enterprise Accreditation Secured:** Fakeeh Care became the first private healthcare provider in the Kingdom to achieve JCI Enterprise Accreditation on a group level, a system-wide validation covering governance, quality, patient-safety protocols and standardized clinical processes across all facilities—building on earlier facility-level accreditations and strengthening cross-network consistency as the Group scales.

Commenting on the Group's performance, FCG's President Dr. Mazen Soliman Fakeeh said:

"In the second quarter of the year, Fakeeh Care Group revenues reached to SAR 812 million, posting a solid 24% year on year growth thanks to a 16% year-on-year growth of patients served and a richer case mix. Jeddah's year-on-year expansion in census and revenue continues to demonstrate the strength of our brand and clinical depth, while Riyadh's disciplined ramp-up continues to progress—together with the recently opened DSFH Madinah—our geographic reach continues to broaden. Our platform remained a robust earnings engine with Attributable to Shareholders profits reaching SAR 154 million in the first half (SAR 82M in 2Q25) or 28% up year-on-year, after absorbing the anticipated start-up operating losses from ramping facilities—investments that are underpinning our multi-year growth trajectory.

Our integrated ecosystem—with tertiary hospitals, medical centers, home healthcare, emergency medical services, medical education, technology and retail medical offerings—continues to differentiate Fakeeh Care. We continue to invest in our digital infrastructure, embedding tools that optimize patient journeys, enhance resource utilization, and reinforce our value-based care model, elevating patient-reported outcomes and experience. We progressed with the construction of the Alawali (Makkah) and North Obhur (Jeddah) medical centers and completed the design process and broke ground on DSFMC Al Zahraa, a key spoke in our hub-and-spoke model. Furthermore, achieving JCI Enterprise Accreditation as the first private healthcare group in the Kingdom validates our governance, safety culture, standardized clinical pathways and enterprise risk systems. It affirms that the quality DNA forged in our flagship facilities scales consistently across every new node we activate, safeguarding patient outcomes as we grow.

During the quarter, it was our privilege to partner with the Kingdom's leadership in service of pilgrims through the mobilization of ambulatory teams and ambulances, and the CSR operation of Namira Hospital during the Hajj period. Our emergency medical services teams supported safe, coordinated care at national scale—deepening our relationship with public health institutions and reflecting our commitment to the Kingdom's broader societal mission. These deployments showcase Fakeeh Care Group's readiness to contribute further to upcoming public-private partnerships and privatization initiatives where a reliable, data-driven private-health-care ecosystem can add immediate value.

Looking ahead, our priorities are clear: drive utilization across our ramping facilities with strategic case-mix refinement in Jeddah and Riyadh; execute a disciplined, quality-first ramp in Madinah; advance milestones across our growth agenda; and continue embedding digital and data-driven workflows that unlock efficiency while elevating care standards. We aim to further broaden our preventative medicine and early-intervention offerings, strengthening longitudinal patient engagement. Throughout, we remain disciplined in capital deployment—preserving a conservative balance sheet as we fund expansion and cement the foundation for a highly scalable and sustainably profitable healthcare ecosystem. With a resilient mature platform, a scalable operating model, and a deepening role in the Kingdom's healthcare transformation, we are well positioned to create enduring value for patients, staff, students, shareholders and the broader community."

Total Patients Served

(No. of patients / Bed occupancy %)



Outpatient Visits

('000)



Inpatient Admissions

('000)



Operational & Strategic Developments

Fakeeh Care Group served more than **465 thousand patients** in 2Q25, a **16%** year-on-year increase that lifted 1H25 volumes to **897 thousand**. Group-wide in 2Q25, outpatient and inpatient volumes rose **15% and 16% YoY respectively**, while surgical procedures grew **22%**, continuing to refine the Group's acuity mix toward higher-value care.

Operational capacity expanded to **565 beds** in 2Q25 up **15% YoY** and represents **68%** of the Group's 835 maximum bed capacity. The increase reflects the first **48 beds** recently opened at DSFH Madinah and **31 beds** added at the ramping-up facility in Riyadh. Jeddah averaged **88% utilization** in 2Q25 and Riyadh **66%**; including the start-up dilution from Madinah, consolidated utilization was **80%**.

Jeddah continued to anchor performance, with paid outpatient visits up **14%** and inpatient admissions up **13%** in 2Q25 versus 2Q24 (note: the prior-year quarter included more Ramadan/Eid days leading to lower net working days). For 1H25, Jeddah outpatients and inpatients census grew by **6% and 4% YoY respectively**. Growth was sustained through optimization programs that focus on streamlining clinical pathways, perioperative scheduling, and around the clock discharge protocols that collectively aim to reduce average length of stay in line with global Value-Based Healthcare practices. The flagship hospital's legacy and sub-specialty offerings enable it to attract patients in a competitive market supported by preferred patient outcomes.

In Riyadh, the ramp-up continues to gain momentum. The hospital added **31 beds** over the past 12 months, bringing 2Q25 operational capacity to **102 beds** (vs **71** in 2Q24). In 2Q25, outpatient and inpatient volumes grew **28% and 33% YoY**, leading to growth in 1H25 of **22%** and **26%** respectively. Surgical procedures surged **146% YoY** in 2Q25 and **97% YoY** for 1H25. Utilization stood at **66%** in 2Q25 (**72%** in 2Q24), reflecting the larger bed base within the hospital. Management plans to introduce **16** new beds before year-end 2025 and to launch a high-demand mental-health service, while expanding oncology and IVF service offerings, further refining the hospital's case mix.

DSFH Madinah opened in 2Q25 with an initial **48 beds** (of **200 capacity**), launching core medical services supported by Group-wide integrated resources and infrastructure. Phased specialty additions, using the quality-first activation approach applied in Riyadh, coupled with the finalization of strategic payor agreements are expected to support gradual occupancy gains through 2026 and beyond as the facility transitions from its start-up phase to ramp-up.

Strengthening the Integrated Healthcare Platform

Home Healthcare
(SAR mn)



Education
(SAR mn)



- **Home Healthcare**: In 1H-2025, the division increased its visits by over 100% from 43 thousand to 86 thousand and grew revenue to over SAR 40 million in 1H-2025 versus SAR 20.8 million in 1H-2024. Operating as an integrated standalone entity, through six branches (Jeddah, Riyadh, Madinah, Makkah, Abha, and Dammam), giving it a foothold across the western, central, and eastern provinces. Two additional sites are slated to open by 4Q25 in North Jeddah's rapidly developing Obhur district and in Yanbu, a strategic hub for petro-chemical operations. The network is targeted to reach 13 branches by end-2027, creating a nationwide "umbrella" coverage and fortifying the Group's Home Healthcare business as the Kingdom's largest standalone home-healthcare provider. Services span TPN, diagnostic radiology, wound management, dental care, home haemodialysis, and physiotherapy—ensuring holistic, patient-centred care in alignment with Vision 2030 goals.

- **Fakeeh College for Medical Sciences (FCMS):** FCMS—the Group's accredited academic arm—offers MBBS, Nursing, Pharmacy, Medical Laboratory Sciences, and Respiratory Care degrees, plus master's and joint-supervision PhD tracks under the NCAAA. Average LTM active students reached 1,723 students in 2Q-25 (1,659 in 2Q-24), supported by a 7:1 student-to-faculty ratio with students achieving a 95% first-time pass rate on the Saudi Commission exam. The new 6,500-sqm Simulation & Clinical Skills Centre—featuring 15 classrooms, 12 labs, and 18 OSCE rooms capable of training 500 students daily—is completed and will accept the September 2025 intake, pairing rigorous academics with rotations across the Group's hospitals, building a pipeline of practice-ready professionals who advance Saudi Vision 2030's goal of localizing world-class healthcare talent.

- **Expansionary Updates:** Fakeeh Care Group has broken ground on its built-to-suit DSFMC Al Zahraa, a new medical center in Jeddah's Al-Zahraa District, developed in partnership with Yasser Yousef Naghi Investment Company. Designed as a key spoke in the Group's hub-and-spoke expansion strategy, the facility will house day surgical suites, a 24/7 emergency department, an integrated diagnostic hub, an assisted reproductive technology unit, and an oncology service offering, extending the Group's comprehensive high-quality care within proximity of the community.

- **Fakeeh Emergency Medical Services (MedE)** The Group fulfilled a Saudi Red Crescent tender to deploy 725 emergency-response teams with over 3,500 paramedics and 30 ambulances for the 2025 Hajj season. This Saudi Red Crescent Authority award certifies the Group's emergency response capabilities and marks another important step in expanding the Group's leadership in emergency medical services and delivering critical healthcare support at a national scale. This tender also recognizes the Group's strength in securing public tenders on the back of its holistic and integrated operational ecosystem. Worth noting, the Group operates the largest private ambulatory fleet in the Kingdom with 79 ambulances as of 1H25.

- **Innovative Healthcare Solutions:** Fakeeh Care Group's Tech arm engineered and now operates "Medical Capsules" that are self-contained, all-weather virtual clinics that fit into underserved neighbourhoods, corporate campuses, and public venues. Each mobile unit houses a suite of connected diagnostics (BP, ECG, BMI, glucose, temperature, and more) and display that links patients to remote physicians via a secure cloud platform. Results, notes, and prescriptions can be printed on-site, dramatically expanding access to primary care while maintaining Fakeeh-level quality.

- **Public Partnerships:** In 2024 we piloted a fully equipped Mina medical facility that treated pilgrims around the clock under a pioneering public-private model. Building on that success, the partnership deepened in the 2025 Hajj season, whereby Fakeeh Care became the medical operator of Namira Hospital on a full CSR basis, mobilizing 250-plus clinicians and support staff to cover ICU and heat-stroke units, laboratory and radiology services, inpatient and outpatient wards, a 24-hour emergency department, and an on-site pharmacy—delivering comprehensive, high-acuity care to thousands of pilgrims at peak demand.



- **Global Accreditations:** Fakeeh Care Group has become the Kingdom's first private healthcare group to earn Joint Commission International (JCI) Enterprise Accreditation—a rigorous, system-wide endorsement that evaluates everything from governance and strategy to equipment procurement and sterilization practices across all facilities. Building on its 2006 milestone, when Dr. Soliman Fakeeh Hospital secured Saudi Arabia's first private-hospital JCI accreditation, this new honour caps 47 years of the Group's deeply rooted culture of quality and affirms its ability to standardize world-class practices, elevate patient safety, and boost operational efficiency.









Financial Review

Strong revenue growth drives robust profitability through a favourable business mix and optimized cost structure

Fakeeh Care Group delivered **SAR 812 million** in revenue in 2Q25, up **24%** year on year (2Q24: **SAR 654 million**) as patient volumes rebounded post-Ramadan, Jeddah sustained double-digit growth, while the Riyadh ramp along with the other verticals contributed a larger share of Group turnover. As a result, 1H25 revenue rose **13% to SAR 1.51 billion** (1H24: **SAR 1.33 billion**).

Revenue expansion in the current quarter was powered by higher patient volumes—outpatient visits and inpatient admissions rose **15% and 16%** respectively year on year—translating into combined revenue growth of **18%**. Year-to-date, outpatient and inpatient volumes increased **8%** and **7%**, while related combined gross revenues rose by **11%**. Pricing and case-mix tailwinds added support to the average revenue per outpatient visit and inpatient admission contributing **3%** YTD on a consolidated revenue level.

Within Healthcare operations, Jeddah remains the largest revenue contributor albeit Riyadh's role continued to increase as capacity continued to ramp, and case mix refined. Notably contributions from other business lines risen, including the seasonal Red Crescent business in MedE, as the Group's geographic reach continues to broaden and ancillary business grows. Core Healthcare operations accounted for **92%** in 1H25, increasing **15%** YTD. Education contributed **4%** (up **8%** YTD). The remaining contribution came from medical-related, IT and complementary services—including retail offerings such as Fakeeh Vision—which grew **4%** YTD in aggregate.

Operating Costs Analysis

Group cost Sales increased **28%** YoY in 2Q25 to **SAR 631 million**, compressing gross margin to **22.2%** (**24.7%** in 2Q24). Accordingly, 1H25 cost of revenue rose **17.5%** to **SAR 1.16 billion** with gross margin at **23.6%** compared to 26.3% in 1H24. Despite the rise in Cost of Revenue, Gross Proft in 2Q25 increased YoY by **11.6%** and in 1H25 by **1.8%** supported by the overall strong revenue growth.

The increase in cost of sales was driven primarily by front-loaded clinical labour and under-absorbed fixed costs as capacity was added in Madinah and Riyadh; sector wage inflation and talent-retention initiatives also contributed, lifting salaries and related benefits to **41%** of revenue YTD (**38%** in 1H24). Procurement discipline and integrated sourcing held consumables at **22%** of revenue (**23%** in 1H24) and maintained other direct costs at **12%**, partially offsetting staff costs pressure.







Cash balances as of June 2025 include Sukuk amounting to SAR 197 mn & SAR 196 mn as of December 2024



**In FY24 the Group reported Net Cash of SAR 193 million, in 1H25 the Group reported Net Debt of 104 million.*

Group operating expenses remained tightly controlled. Selling, general and administrative costs held at 12 % of revenue in both 2Q25 and 1H25—unchanged from prior periods—as the larger revenue base offset higher support needs, including the one-off expense of operating Namira Hospital on a full CSR basis. Early benefits from scale of business and centralizing further selected non-medical support functions contributed to holding the ratio stable.

Operating Profitability analysis

Group EBITDA reached **SAR 129 million** in 2Q25 (2Q24: **SAR 116 million**), with a **15.9% margin** (17.8%). Strong performance in 2Q25, drove 1H25 EBITDA to **SAR 250 million** (1H24: **SAR 259 million**), leading to a margin of **16.5%** (19.4% in 1H24). Margin dilution reflects ramp effects, increased labour intensity—most notably DSFH Madinah's start-up—and higher provisioning for receivables reflecting larger billing volumes and proactive provisioning; however, underlying collection quality remains stable.

Net Profit

Despite ramp up related dilution, Net Profit rose **59% YoY** in 2Q25 to **SAR 68 million** (2Q24: SAR 43 million) and by **31% YoY** in 1H25 to **SAR 136 million** (1H24: SAR 104 million), driven by business performance strength, lower finance costs and higher finance income. Similarly, Profits attributable to Shareholders grew **73%** to **SAR 82 million** (2Q25: SAR 48 million) and by **28%** in 1H25 to **SAR 154 million** (1H24: SAR 120 million). Accordingly, EPS read **SAR 0.67** in 1H25, up **14%** from 1H24.

Balance Sheet, Liquidity & Capital Deployment

Fakeeh Care's total assets in June 2025 stood at **SAR 5.6 billion**, up **5%** from year-end 2024, reflecting continued investment in network expansion and working-capital build to support higher activity levels. Total CAPEX booked year to date amounted to **SAR 282.3 million** (including intangible assets), as the Group progressed with the completion of Madinah Hospital, the Medical Centers in Jeddah and Makkah, and its educational service offerings plans to commence prior to 2025/2026 student intakes. A detailed update on the Group's ongoing projects is provided in the annexure to this report.

Total loans (long & short-term) totalled **SAR 578.6 million** on 30 June 2025, increased by **SAR 42.1M** from December 2024 (**SAR 536.5 million**). On the other hand, Cash & cash equivalents including short-dated Governmental Sukuk **(SAR 197 million)** stood at **SAR 474.3 million.** As a result, the Group's net debt position of **SAR 104 million** as of 1H25 translates to **0.20x Net Debt/LTM EBITDA**. Including lease liabilities of **SAR 495.8 million**, Net Debt/LTM EBITDA reads **1.17x**. That said, the Group retains meaningful liquidity headroom through a combination of cash on hand, undrawn facilities, and strong cash generation from the mature business platform. Management remains comfortable funding ongoing growth in Madinah and the Group's other growth initiatives within the balance-sheet's capacity.

Fakeeh Care Group Status of Upcoming Projects

Project	Location	Capacity	Status - updated	Completion
DSFMC Alawali	Makkah, Alawali	**Clinics:**20 **Day Surgery Units:** 2	Construction in progress by our 100% subsidiary Advance Horizon Company (AHC)	2H-2025
DSFMC North Obhur	Jeddah, North Obhur	**Clinics:**22 **Day Surgery Units:** 2	Land acquired and construction in process	1H-2026
DSFMC Al Zahra	Jeddah, Al Zahra	**Clinics:** 60	Construction in progress	1H-2026
DSFMC Al Hamra	Riyadh, Al Hamra	**Clinics:**22 **Day Surgery Units:** 2	Construction in progress	2H-2026
DSFH Jeddah Surgery Tower Extension	Jeddah, Al Hamra	**Beds:** 140 **Operating Theatres:** 13	Permits in process of being obtained	1H-2028
HEAL Neuroscience, Rehabilitation & Long-term Care Hospital	Jeddah, Al Zahra	**Beds:** 200	A comprehensive medical facility fully owned by the Group which will replace Project Al Hamra	1H 2028
DSFH Makkah	Makkah, Masar	**Beds:** 200 **Operating Theatres:** 7	Land leased for 40 years, designer appointed, and schematics submitted for approval; excavation and groundwork in progress	1H-2028
DSFH South Obhur	Jeddah, South Obhur	**Beds:** 300 **Operating Theatres:** 11	Land acquired and designer (HKS) appointed	2H-2028

– Ends –

About Fakeeh Care Group

Established in 1978 by the late Dr. Soliman Fakeeh, the Fakeeh Care Group stands as a pioneer in integrated healthcare services in Saudi Arabia. Our comprehensive healthcare offering includes our core healthcare services ranging from ambulatory care to secondary and tertiary care, supported by Emergency Medical Services and Fakeeh Home Healthcare. Additionally, our offerings are enhanced by our industry-leading academic healthcare programs. Building on a strong track record of growth in our home city of Jeddah, the Group embarked on a Kingdom-wide expansion strategy to bring our well proven hub-and-spoke model and medical support services to major cities across Saudi Arabia.

In June 2024, Fakeeh Care Group successfully concluded its initial public offering (IPO) on the Tadawul. The IPO raised gross proceeds of SAR 2.9 billion (US$ 764 million) for the Company and the Selling Shareholders of which SAR 1.7 billion will be used to support and accelerate the Group's growth strategy.

For further information, please contact:

Mr Waleed Hamed
Investments & Investor Relations Director
Email: wahamed@fakeeh.care

Mr Panagiotis (Panos) Chatziantoniou
Group CFO
e-mail: investors@fakeeh.care

Forward-looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding the Company's business and management, its future growth or profitability and general economic and regulatory conditions and other matters affecting it.

These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and its investments, including, among other things, the development of its business, financial condition, prospects, growth, strategies, as well as the trends in the industry and macroeconomic developments in the Kingdom of Saudi Arabia. Many of these risks and uncertainties relate to factors that are beyond the Company's control or accurate estimation, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and any changes in applicable laws or regulations or government policies. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not otherwise occur and past performance shall not be taken as a guarantee of future results. No representation or warranty is made pertaining to any forward-looking statement made by the Company. The Company does not intend to update, supplement, amend or revise any such forward-looking statement whether as a result of new information, future events or otherwise. Nothing in the Information shall be construed as a profit forecast.

The Information may include financial information that are not defined or recognized under the International Financial Reporting Standards (IFRS). These measures are derived from the Company's consolidated financial statements and provided as additional information to complement IFRS measures. Any financial information provided by the Company should not be considered in isolation or as a substitute for analysis of the Company's financial information as reported under the IFRS.

Consolidated Income Statement

SAR millions	2Q-2025	2Q-2024	YoY %	1H-2025	1H-2024	YoY %
Revenue	811.8	654.0	24.1%	1,512.9	1,334.4	13.4%
Costs of revenue	(631.2)	(492.2)	28.3%	(1,156.1)	(983.9)	17.5%
Gross profit	**180.6**	**161.9**	**11.6%**	**356.8**	**350.5**	**1.8%**
Gross profit margin	***22.2%***	***24.7%***	***-2.5pp***	***23.6%***	***26.3%***	***-2.7pp***
Other income	5.4	5.8	-7.6%	7.0	7.8	-9.7%
General and administrative expenses	(76.5)	(75.3)	1.5%	(150.9)	(144.4)	4.5%
Selling and marketing expenses	(20.2)	(12.4)	62.6%	(37.0)	(25.9)	42.9%
Long-term Incentive Plan	(1.5)	0.0	-	(3.8)	0.0	-
Impairment loss on receivables	(6.3)	(2.8)	124.3%	(13.4)	(5.6)	139.1%
Operating profit	**81.6**	**77.2**	**5.7%**	**158.6**	**182.3**	**-13.0%**
Operating Profit margin	***10.1%***	***11.8%***	***-1.7pp***	***10.5%***	***13.7%***	***+1.3pp***
Finance cost	(10.0)	(34.7)	-71.1%	(19.9)	(74.0)	-73.0%
Finance income	5.4	5.1	5.6%	13.1	7.0	86.8%
Profit before Zakat	**77.0**	**47.6**	**61.7%**	**151.8**	**115.3**	**31.6%**
Zakat	(8.8)	(4.8)	85.7%	(16.3)	(11.8)	38.0%
Profit after Zakat	**68.2**	**42.9**	**59.0%**	**135.5**	**103.6**	**30.9%**
Profit margin	***8.4%***	***6.6%***	***+1.8pp***	***9.0%***	***7.8%***	***+1.2pp***
Profit for the year attributable to:						
Shareholders' of the Company	**82.1**	**47.5**	**73.0%**	**154.3**	**120.2**	**28.4%**
Non-controlling interest	(14.0)	(4.6)	203.2%	(18.8)	(16.6)	13.1%
Additional information:						
EPS[1]	0.36	0.23	53.7%	0.67	0.59	14.0%
EBITDA	**129.1**	**116.2**	**11.2%**	**250.2**	**258.7**	**-3.3%**
EBITDA margin	***15.9%***	***17.8%***	***-1.9pp***	***16.5%***	***19.4%***	***-2.9pp***

[1] *Earnings per share (EPS) is calculated based on attributable net profit and the weighted average number of shares which reads 230,000,000 shares as of 1H25, and 204,286,000 as of 1H24.*

Consolidated Balance Sheet

SAR 000'	30-Jun-25	31-Dec-24
ASSETS		
Property and equipment	2,322,220	2,095,843
Right-of-use assets	465,119	505,338
Intangible assets and goodwill	542,264	543,980
Investment properties	397	417
Financial asset at amortized cost	197,008	195,604
Prepayments and other non-current assets	14,556	15,024
Other long-term receivables	114,610	117,716
Non-current assets	**3,656,174**	**3,473,922**
Inventories	207,014	178,727
Accounts and other receivables	1,240,862	895,520
Contract assets	95,133	68,549
Prepayments and other current assets	128,010	171,122
Cash and cash equivalents	277,266	533,785
Current assets	**1,948,285**	**1,847,703**
TOTAL ASSETS	5,604,459	5,321,625
EQUITY		
Share capital	232,000	232,000
Treasury shares	(2,000)	(2,000)
Share premium	1,653,473	1,653,473
Retained earnings	1,150,974	1,061,873
Equity attributable to shareholders of the Company	**3,034,447**	**2,945,346**
Non-controlling interests	393,650	374,078
Total equity	**3,428,097**	**3,319,424**
LIABILITIES		
Long-term loans	331,000	321,500
Lease liabilities	439,905	481,208
Employees' end of service benefits	278,627	260,689
Non-current liabilities	**1,049,532**	**1,063,397**
Short-term loans	247,611	215,000
Current portion of lease liabilities	55,920	60,186
Accounts payables	386,183	372,900
Accrued and other current liabilities	422,644	265,234
Accrued zakat	14,472	25,484
Current liabilities	**1,126,830**	**938,804**
Total liabilities	**2,176,362**	**2,002,201**
TOTAL EQUITY AND LIABILITIES	5,604,459	5,321,625
Additional information:		
Loans less cash (net debt)	301,345	2,714
Total Net debt (including leases)	600,162	348,505
Net Debt / Equity	0.088	0.001
Total Net Debt / Equity	0.23	0.16
12 months rolling EBITDA	513,425	521,948
Net Debt / EBITDA	0.587	0.005
Total Net Debt / EBITDA	1.55	1.04